Abstract:ID 87867 Poster Board 474 The combined inhibition of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) represents a novel approach to non-opioid pain management, drawing from the known functions of these enzymes in pain and inflammatory pathways. Using multi-target directed ligands (MTDLs), a medicinal chemistry approach where a single drug modulates two or more biological targets simultaneously, our lab previously identified several benzothiazole-phenyl MTDLs with potent dual sEH and FAAH inhibition. Here, we report several in vivo evaluations of our previously identified dual sEH/FAAH inhibitor SP 4-5, the data received from National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP) and a follow-up structure-activity relationship (SAR) study of quinolinyl-phenyl-based MTDLs that were synthesized using a microwave-assisted Suzuki coupling reaction. SP 4-5 was evaluated against persistent inflammatory pain. An intraplantar injection of Complete Freund's Adjuvant (CFA) was used to induce hindpaw inflammation. 1 and 3 mg/kg SP4-5 were administered 24 hours after inflammation. Neither dose alleviated mechanical or thermal hypersensitivity. However, when administered 2.5 hours after CFA, 3 mg/kg SP4-5 increased mechanical withdrawal thresholds indicating antinociception. In addition, PDSP screening showed that SP 4-5 does not bind to delta, mu and kappa opioid receptors. Our SAR study showed that quinoline moiety can successfully replace benzothiazole ring yielding potent compounds in human FAAH and human, rat, and mouse sEH inhibition assays. The most potent dual sEH/FAAH inhibitor identified in this study, JA112, showed inhibition potency in the low nanomolar range (1.7 nM -17.2 nM) for human FAAH, human sEH, rat sEH and mouse sEH enzymes. JA-112 was evaluated for its ability to reverse acute inflammatory induced by an intraplantar injection of dilute formalin. This revealed that JA-112 produces antinociception against formalin-induced inflammatory pain. Further, the differences observed between Phase 1 and Phase 2 of the Formalin Test indicate that JA-112 produces antinociception in a manner consistent with drugs that prevent pro-inflammatory states such as non-steroidal anti-inflammatory drugs (i.e., in non-opioid manner). Future experiments will investigate the effects of JA-112 against persistent inflammatory pain states and determine any adverse effects. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1 R16GM149204-01.

Mechanisms involved in the antinociceptive and anti-inflammatory effects of a new triazole derivative: 5-[1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1H-tetrazole (LQFM-096)

Pharmacological evaluation and molecular docking of new di-tert-butylphenol compound, LQFM-091, a new dual 5-LOX/COX inhibitor

Molecular docking and pharmacological/toxicological assessment of a new compound designed from celecoxib and paracetamol by molecular hybridization

Evaluation of the systemic and spinal antinociceptive effect of a new hybrid NSAID tetrahydropyran derivative

Anti-inflammatory and antinociceptive effects, and safety toxicological profile of a new paracetamol analog, LQFM291

Limonene, a citrus monoterpene, non-complexed and complexed with hydroxypropyl-β-cyclodextrin attenuates acute and chronic orofacial nociception in rodents: Evidence for involvement of the PKA and PKC pathway

Neuromodulation of acid‐sensitive ion channels (ASICs) and anti‐inflammatory potential by Lichenxanthone in adult zebrafish (Danio rerio): Experimental and docking studies

Anti-inflammatory and Antinociceptive Effects of 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine in Mice

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Antinociceptive Effects of the Novel Spirocyclopiperazinium Salt Compound LXM-10 in Mice.

Evaluation of the in vivo and in vitro anti-inflammatory activity of a new hybrid NSAID tetrahydropyran derivative

Anti-hypernociceptive and anti-inflammatory effects of JM-20: A novel hybrid neuroprotective compound

β-Lactam TRPM8 Antagonists Derived from Phe-Phenylalaninol Conjugates: Structure-Activity Relationships and Antiallodynic Activity

Synthesis and biological evaluation of N-(benzene sulfonyl)acetamide derivatives as anti-inflammatory and analgesic agents with COX-2/5-LOX/TRPV1 multifunctional inhibitory activity

Oral treatment with methanolic extract of the root bark of Condalia buxifolia Reissek alleviates acute pain and inflammation in mice: Potential interactions with PGE2, TRPV1/ASIC and PKA signaling pathways

Preparation and in Vivo Antinociceptive Behavior of Four New 2‐amino‐6‐trifuromethoxybenzothiazole Carboxylic Acid Derivatives

Analgesic Activities of the Mixed Opioid and NPFF Receptors Agonist DN-9 in a Mouse Model of Formalin-Induced Orofacial Inflammatory Pain.

Antinociceptive Mechanism of the Spirocyclopiperazinium Compound Lxm-10 in Mice and Rats

An In Silico Approach to Exploring the Antinociceptive Biological Activities of Linalool and its Metabolites

Analgesic Effect of Zanthoxylum nitidum Extract in Inflammatory Pain Models Through Targeting of ERK and NF-κB Signaling.

Multitarget-Directed Ligands with Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Inhibitory Activities for Treatment of Chronic Pain